Intellia Therapeutics Inc...

NASDAQ: NTLA · Real-Time Price · USD
11.02
0.12 (1.10%)
At close: Aug 15, 2025, 3:37 PM

Intellia Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
57.88M 36.27M 52.12M 33.05M
Cost of Revenue
10.29M 8.98M 7.57M 6.89M
Gross Profit
47.59M 27.3M 44.55M 26.16M
Operating Income
-534.26M -515.29M -458.16M -267.85M
Interest Income
47.81M 49.83M 8.54M 1.28M
Pretax Income
-519.02M -481.19M -474.19M -267.89M
Net Income
-519.02M -481.19M -474.19M -267.89M
Selling & General & Admin
125.83M 116.5M 90.31M 71.1M
Research & Development
466.31M 435.07M 419.98M 229.81M
Other Expenses
-10.29M -8.98M -7.57M -6.89M
Operating Expenses
581.86M 542.59M 502.71M 294.01M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
592.14M 551.57M 510.29M 300.9M
Income Tax Expense
n/a n/a 16.02M -8.17M
Shares Outstanding (Basic)
98.85M 88.77M 76.97M 70.89M
Shares Outstanding (Diluted)
98.85M 88.77M 76.97M 70.89M
EPS (Basic)
-5.25 -5.42 -6.16 -3.78
EPS (Diluted)
-5.25 -5.42 -6.16 -3.78
EBITDA
-523.98M -506.31M -450.59M -260.96M
EBIT
-534.26M -515.29M -458.16M -267.85M
Depreciation & Amortization
10.29M 8.98M 7.57M 6.89M